Bromocriptine induced pleuropulmonary fibrosis.

Bromocriptine induced pleuropulmonary fibrosis.

Pergolide-induced pleuropulmonary fibrosis.

Pleuropulmonary fibrosis is a rare, but well-recognized adverse effect of ergot alkaloids. We report on four patients who developed pleural and/or pulmonary fibrosis during treatment with pergolide and give characteristics of 87 cases with one or more symptoms of serosal fibrosis. Retroperitoneal and pleuropulmonary fibrosis are serious conditions, which are often irreversible after drug withdr...

Pleuropulmonary involvement during bromocriptine treatment.

The use of bromocriptine in the treatment of Parkinson's disease is increasing. More than 20 cases of suggested drug-induced pleuropulmonary disorders during bromocriptine therapy have been reported. We describe four male parkinsonian patients taking bromocriptine in whom pleuropulmonary abnormalities were discovered in a pulmonary hospital during a one-year period. In only one case were the ro...

Bromocriptine-induced psychosis in acromegaly.

Dopaminergic mechanisms have been implicated in the pathogenesis of schizophrenia.' Psychosis induced by the dopamine-receptor agonist bromocriptine has been described mainly with high-dose regimens in Parkinsonism and less frequently with the lower doses used in hormonal disorders.24 The following case is of interest because of the insidious onset of psychosis and the family history of paranoi...

Pleuropulmonary fibrosis associated with chronic and excessive intake of ergotamine.

Retroperitoneal, pleuropulmonary, and endocardial fibroses are relatively uncommon but serious side effects of the prophylactic antimigraine drug methysergide.1 2 Ergotamine is a potent drug in the treatment of the migraine attack, and is chemically related to methysergide. Retroperitoneal fibrosis has been reported in ergotamine users3-' and recently the occurrence of pleuropulmonary fibrosis ...